Important Notice to Long-term Shareholders of RxSight, Inc. (RXST): Grabar Law Office Investigates Claims on Your Behalf

Philadelphia, Pennsylvania--(Newsfile Corp. - July 24, 2025) - Grabar Law Office is investigating claims on behalf of shareholders of RxSight, Inc. (NASDAQ: RXST). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased RxSight, Inc. (NASDAQ: RXST) shares prior to November 7, 2024, and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/rxsight-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Alternatively, if you purchased your shares between November 7, 2024, and July 8, 2025, you can participate in the class action.

WHY? According to a recently filed underlying federal securities fraud class action complaint, it is alleged that RxSight, Inc. (NASDAQ: RXST), via certain of its officers, made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, the Complaint alleges Defendants failed to disclose to investors that: (1) the Company was experiencing "adoption challenges" and/or structural issues resulting in declines in sales and utilization; (2) Defendants had overstated the demand for RxSight's products; (3) as a result, RxSight was unlikely to meet its own previously issued financial guidance for fiscal year 2025; and (4) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On July 8, 2025, RxSight revealed significant declines in LDD sales, LAL utilization, and overall revenue in Q2 2025, also lowering its full-year 2025 revenue guidance. CEO Ronald Kurtz disclosed at that time that "[a]doption challenges over the last few quarters have been a primary reason for the LDD stall." On this news, RxSight shares fell $4.84, or 37%, to a close of $7.95 per share on July 9, 2025.

WHAT YOU CAN DO NOW: If you purchased RxSight, Inc. (NASDAQ: RXST) shares prior to November 7, 2024, and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/rxsight-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. If, alternatively, you purchased your shares between November 7, 2024, and July 8, 2025, you can participate in the class action. $RXST #RxSight

Attorney Advertising Disclaimer

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/259959